Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V940 plus pembrolizumab versus placebo plus pembrolizumab in first-line metastatic melanoma
2024-519605-36-00Phase 2Suspended
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in cutaneous melanoma (CM) comparing V940 + pembrolizumab with Placebo to V940 + pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Started Aug 2025; status: suspended.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-519605-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519605-36-00.